Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion of 12-week follow up anticipated by year end with data shortly thereafter SSRI drug interaction study initiated MHRA approval for new SPL026 trial LONDON, Oct. 14, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “…
